Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

As another clinical trial of a mitochondria-targeting cancer therapy faces failure, it calls for a thorough re-evaluation of the strategy; the time has come to go from the bedside back to the bench.

A study showing feasibility and preliminary efficacy of off-the-shelf CAR T cells represents steady progress on the long road to clinical use.

A smartphone-based system, designed to induce a steady gaze in children using cartoon-like video stimuli, can identify visually impaired children across a wide range of ophthalmic disorders, based on analysis of gazing behaviors and facial features.

Patients with BRAF^V600E-mutated colorectal cancer have encouraging overall response rates to inhibition of PD-1, BRAF and MEK, with translational analyses suggesting that induction of tumor-intrinsic programs and immune programs contributes to improved outcomes via MAPK inhibition.

Genomic analyses in large cohorts of patients with cancer identify a new measure of tumor mutational burden, based on genomic regions that are unlikely to undergo loss, that is associated with therapeutic response to immunotherapy.

In an interim phase 1 trial analysis, escalating doses of off-the-shelf allogeneic anti-BCMA CAR T cells, in combination with an anti-CD52 antibody-containing lymphodepletion regimen, were feasible to administer and exhibited an encouraging safety profile in patients with relapsed or refractory multiple myeloma

Federated learning improves prediction of the histological response to neoadjuvant chemotherapy in patients with triple-negative breast cancer, demonstrating the feasibility of this approach for analysis of multicenter cohorts of patients with rare diseases.

A mitochondrial complex I inhibitor exhibited dose-limiting toxicities, including neurotoxicity, in patients with acute myeloid leukemia and solid tumors, warranting further studies to evaluate the mechanism linking oxidative phosphorylation inhibition and neurotoxicity.

The drug-scheduling system, particularly the approach to rescheduling, should be reformed to ensure all beneficial medicines, including marijuana and psilocybin, are available to scientists and patients.

A large study finds that offering cash for vaccination does not have unintended negative consequences — providing much-needed data and alleviating some longstanding concerns.

The US Food and Drug Administration should address health misinformation through existing and new regulatory approaches, including modernizing product labeling, investing in infodemic surveillance and addressing the roles of the internet and social media.

Nature Medicine explores the latest translational and clinical research news, with data from an ongoing clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.

We are launching a series on evidence in medicine, to discuss new approaches to assessing the safety and efficacy of cutting-edge health technologies and treatments.

Artificial intelligence algorithms have had mixed success in health, in part because regulation prevents them from evolving at the necessary rate.